Following Significant Advances at ASCO, Amplia Therapeutics Provides Letter to Shareholders Highlighting the Potential Opportunities for Combination with KRAS Inhibition in Pancreatic CancerMelbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing Director Dr. Chris Burns outlining the potential for the Company’s best-in-class FAK inhibitor narmafotinib in combination with the emerging KRAS inhibitor class following exciting new data presented at the American Society of Clinical Oncology Annual Meeting earlier this month:
